A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
Gabriel N. Hortobágyi, Aleksandra Łacko, Joohyuk Sohn, F. Melo Cruz et autres
us, pl, kr, br, es, ru, tw, de, ie, au, cn (code pays fourni par la source)